{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:43:56Z","timestamp":1789537436221,"version":"build-2803163510"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Medical Research Centre at Hamad Medical Corporation","award":["IRGC-01\u201351-033"],"award-info":[{"award-number":["IRGC-01\u201351-033"]}]},{"DOI":"10.13039\/501100001862","name":"Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning","doi-asserted-by":"publisher","award":["219-2014-837"],"award-info":[{"award-number":["219-2014-837"]}],"id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI100560"],"award-info":[{"award-number":["R01AI100560"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI063517"],"award-info":[{"award-number":["R01AI063517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI072219"],"award-info":[{"award-number":["R01AI072219"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cleveland Department of Veterans Affairs","award":["1I01BX001974"],"award-info":[{"award-number":["1I01BX001974"]}]},{"name":"Biomedical Laboratory Research & Development Service of the VA Office of Research and Development"},{"name":"Geriatric Research Education and Clinical Center VISN 10"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the in vitro activity of ceftazidime\/avibactam and ceftolozane\/tazobactam against clinical isolates of MDR Pseudomonas aeruginosa from Qatar, as well as the mechanisms of resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>MDR P. aeruginosa isolated between October 2014 and September 2015 from all public hospitals in Qatar were included. The BD PhoenixTM system was used for identification and initial antimicrobial susceptibility testing, while Liofilchem MIC Test Strips (Liofilchem, Roseto degli Abruzzi, Italy) were used for confirmation of ceftazidime\/avibactam and ceftolozane\/tazobactam susceptibility. Ten ceftazidime\/avibactam- and\/or ceftolozane\/tazobactam-resistant isolates were randomly selected for WGS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 205 MDR P. aeruginosa isolates were included. Of these, 141 (68.8%) were susceptible to ceftazidime\/avibactam, 129 (62.9%) were susceptible to ceftolozane\/tazobactam, 121 (59.0%) were susceptible to both and 56 (27.3%) were susceptible to neither. Twenty (9.8%) isolates were susceptible to ceftazidime\/avibactam but not to ceftolozane\/tazobactam and only 8 (3.9%) were susceptible to ceftolozane\/tazobactam but not to ceftazidime\/avibactam. Less than 50% of XDR isolates were susceptible to ceftazidime\/avibactam or ceftolozane\/tazobactam. The 10 sequenced isolates belonged to six different STs and all produced AmpC and OXA enzymes; 5 (50%) produced ESBL and 4 (40%) produced VIM enzymes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>MDR P. aeruginosa susceptibility rates to ceftazidime\/avibactam and ceftolozane\/tazobactam were higher than those to all existing antipseudomonal agents, except colistin, but were less than 50% in extremely resistant isolates. Non-susceptibility to ceftazidime\/avibactam and ceftolozane\/tazobactam was largely due to the production of ESBL and VIM enzymes. Ceftazidime\/avibactam and ceftolozane\/tazobactam are possible options for some patients with MDR P. aeruginosa in Qatar.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkz379","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T07:19:17Z","timestamp":1565335157000},"page":"3497-3504","source":"Crossref","is-referenced-by-count":33,"title":["Evaluation of in vitro activity of ceftazidime\/avibactam and ceftolozane\/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar"],"prefix":"10.1093","volume":"74","author":[{"given":"Mazen A","family":"Sid Ahmed","sequence":"first","affiliation":[{"name":"Microbiology Division, Hamad Medical Corporation, Doha, Qatar"},{"name":"The Life Science Centre, School of Science and Technology, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad","family":"Abdel Hadi","sequence":"additional","affiliation":[{"name":"Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubaker A I","family":"Hassan","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulieman","family":"Abu Jarir","sequence":"additional","affiliation":[{"name":"Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna A","family":"Al-Maslamani","sequence":"additional","affiliation":[{"name":"Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla Omer","family":"Eltai","sequence":"additional","affiliation":[{"name":"Biomedical Research Center, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M","family":"Dousa","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M","family":"Hujer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA"},{"name":"Louis Stokes Cleveland, Department of Veterans Affairs Medical Center, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A","family":"Sultan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Weill Cornell Medicine-Qatar, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Soderquist","sequence":"additional","affiliation":[{"name":"The Life Science Centre, School of Science and Technology, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA"},{"name":"Louis Stokes Cleveland, Department of Veterans Affairs Medical Center, Cleveland, OH, USA"},{"name":"Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, OH, USA"},{"name":"The CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad Bashir","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Microbiology Division, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Jass","sequence":"additional","affiliation":[{"name":"The Life Science Centre, School of Science and Technology, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5309-6358","authenticated-orcid":false,"given":"Ali S","family":"Omrani","sequence":"additional","affiliation":[{"name":"Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"2019111507203119900_dkz379-B1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ph6111335","article-title":"A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011","volume":"6","author":"Morrissey","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"2019111507203119900_dkz379-B2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2019111507203119900_dkz379-B3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019111507203119900_dkz379-B4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/2049-632X.12033","article-title":"Pseudomonas aeruginosa: new insights into pathogenesis and host defenses","volume":"67","author":"Gellatly","year":"2013","journal-title":"Pathog Dis"},{"key":"2019111507203119900_dkz379-B5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fmicb.2018.00685","article-title":"The versatile mutational resistome of Pseudomonas aeruginosa","volume":"9","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Front Microbiol"},{"key":"2019111507203119900_dkz379-B6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2019111507203119900_dkz379-B7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy","volume":"8","author":"Zavascki","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2019111507203119900_dkz379-B8","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1128\/AAC.00338-07","article-title":"Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.05991-11","article-title":"Prospective multicenter study of the impact of carbapenem resistance on mortality in bloodstream infections","volume":"56","author":"Pe\u00f1a","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B10","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1128\/AAC.00207-10","article-title":"Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes","volume":"54","author":"Tam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B11"},{"key":"2019111507203119900_dkz379-B12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2015.05.003","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam: two novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections","volume":"46","author":"Liscio","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2019111507203119900_dkz379-B13","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"2019111507203119900_dkz379-B14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1128\/AAC.01104-09","article-title":"Activity of a new cephalosporin, CXA-101 (FR264205), against \u03b2-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients","volume":"54","author":"Moya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B15","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B16","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019111507203119900_dkz379-B17","doi-asserted-by":"crossref","first-page":"e01858","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against \u03b2-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B18","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B19","doi-asserted-by":"crossref","first-page":"e00875","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3343\/alm.2017.37.2.174","article-title":"Susceptibility of ceftolozane-tazobactam and ceftazidime-avibactam against a collection of \u03b2-lactam-resistant Gram-negative bacteria","volume":"37","author":"Gonzalez","year":"2017","journal-title":"Ann Lab Med"},{"key":"2019111507203119900_dkz379-B21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2019111507203119900_dkz379-B22"},{"key":"2019111507203119900_dkz379-B23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2019111507203119900_dkz379-B24","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Twenty-Ninth Edition: M100","year":"2019"},{"key":"2019111507203119900_dkz379-B25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cmb.2012.0021","article-title":"SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing","volume":"19","author":"Bankevich","year":"2012","journal-title":"J Comput Biol"},{"key":"2019111507203119900_dkz379-B26","doi-asserted-by":"crossref","first-page":"75.","DOI":"10.1186\/1471-2164-9-75","article-title":"The RAST Server: rapid annotations using subsystems technology","volume":"9","author":"Aziz","year":"2008","journal-title":"BMC Genomics"},{"key":"2019111507203119900_dkz379-B27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1128\/JCM.02981-13","article-title":"Benchmarking of methods for genomic taxonomy","volume":"52","author":"Larsen","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2019111507203119900_dkz379-B28","doi-asserted-by":"crossref","first-page":"421.","DOI":"10.1186\/1471-2105-10-421","article-title":"BLAST+: architecture and applications","volume":"10","author":"Camacho","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"2019111507203119900_dkz379-B29","doi-asserted-by":"crossref","first-page":"1355.","DOI":"10.1128\/JCM.06094-11","article-title":"Multilocus sequence typing of total-genome-sequenced bacteria","volume":"50","author":"Larsen","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2019111507203119900_dkz379-B30","doi-asserted-by":"crossref","first-page":"D566","DOI":"10.1093\/nar\/gkw1004","article-title":"CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database","volume":"45","author":"Jia","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2019111507203119900_dkz379-B31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/AAC.01041-09","article-title":"Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria","volume":"54","author":"Mauldin","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B32","first-page":"1520404.","article-title":"Persistent bacteremia from Pseudomonas aeruginosa with in vitro resistance to the novel antibiotics ceftolozane-tazobactam and ceftazidime-avibactam","volume":"2016","author":"Gangcuangco","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"2019111507203119900_dkz379-B33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019111507203119900_dkz379-B34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019111507203119900_dkz379-B35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/mdr.2014.0121","article-title":"Molecular characterization of carbapenemase production among gram-negative bacteria in Saudi Arabia","volume":"21","author":"Memish","year":"2015","journal-title":"Microb Drug Resist"},{"key":"2019111507203119900_dkz379-B36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1099\/jmm.0.000730","article-title":"Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region","volume":"67","author":"Zowawi","year":"2018","journal-title":"J Med Microbiol"},{"key":"2019111507203119900_dkz379-B37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1128\/AAC.43.3.573","article-title":"Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum \u03b2-lactamase encoded by an Escherichia coli integron gene","volume":"43","author":"Poirel","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1099\/jmm.0.077834-0","article-title":"The molecular basis of \u03b2-lactamase production in Gram-negative bacteria from Saudi Arabia","volume":"64","author":"Yezli","year":"2015","journal-title":"J Med Microbiol"},{"key":"2019111507203119900_dkz379-B39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3201\/eid0703.017322","article-title":"VEB-1-like extended-spectrum \u03b2-lactamases in Pseudomonas aeruginosa, Kuwait","volume":"7","author":"Poirel","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"2019111507203119900_dkz379-B40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jegh.2016.02.002","article-title":"Presence of blaPER-1 and blaVEB-1 \u03b2-lactamase genes among isolates of Pseudomonas aeruginosa from South West of Iran","volume":"6","author":"Davodian","year":"2016","journal-title":"J Epidemiol Glob Health"},{"key":"2019111507203119900_dkz379-B41","doi-asserted-by":"crossref","first-page":"e0180121.","DOI":"10.1371\/journal.pone.0180121","article-title":"Prevalence of ESBL-producing Pseudomonas aeruginosa isolates in Warsaw, Poland, detected by various phenotypic and genotypic methods","volume":"12","author":"Laudy","year":"2017","journal-title":"PLoS One"},{"key":"2019111507203119900_dkz379-B42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1179\/joc.2007.19.2.140","article-title":"Widespread detection of VEB-1-type extended-spectrum \u03b2-lactamases among nosocomial ceftazidime-resistant Pseudomonas aeruginosa isolates in Sofia, Bulgaria","volume":"19","author":"Strateva","year":"2007","journal-title":"J Chemother"},{"key":"2019111507203119900_dkz379-B43","first-page":"19400","article-title":"Prevalence of ESBLs-producing Pseudomonas aeruginosa isolates from different wards in a Chinese teaching hospital","volume":"8","author":"Chen","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"2019111507203119900_dkz379-B44","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1128\/AAC.00047-16","article-title":"Identification of novel VEB \u03b2-lactamase enzymes and their impact on avibactam inhibition","volume":"60","author":"Lahiri","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B45","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1093\/jac\/dkz149","article-title":"ESBLs and resistance to ceftazidime\/avibactam and ceftolozane\/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa","volume":"74","author":"Ortiz de la Rosa","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2019111507203119900_dkz379-B46","doi-asserted-by":"crossref","first-page":"e02085-18","DOI":"10.1128\/mBio.02085-18","article-title":"Deciphering the evolution of cephalosporin resistance to ceftolozane-tazobactam in Pseudomonas aeruginosa","volume":"9","author":"Barnes","year":"2018","journal-title":"mBio"},{"key":"2019111507203119900_dkz379-B47","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1128\/AAC.00825-15","article-title":"Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins","volume":"59","author":"Berrazeg","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B48","doi-asserted-by":"crossref","first-page":"e01183-17","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.01512-08","article-title":"Diversity, epidemiology, and genetics of class D \u03b2-lactamases","volume":"54","author":"Poirel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B50","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/1040841X.2010.481763","article-title":"\u03b2-Lactamases identified in clinical isolates of Pseudomonas aeruginosa","volume":"36","author":"Zhao","year":"2010","journal-title":"Crit Rev Microbiol"},{"key":"2019111507203119900_dkz379-B51","doi-asserted-by":"crossref","first-page":"e01117-17","DOI":"10.1128\/AAC.01117-17","article-title":"In vivo emergence of resistance to novel cephalosporin-\u03b2-lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 \u03b2-lactamase (OXA-539) in sequence type 235 Pseudomonas aeruginosa","volume":"61","author":"Fraile-Ribot","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019111507203119900_dkz379-B52","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(13)70168-3","article-title":"Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study","volume":"13","author":"Edelstein","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2019111507203119900_dkz379-B53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","volume":"21-22","author":"Oliver","year":"2015","journal-title":"Drug Resist Update"},{"key":"2019111507203119900_dkz379-B54","doi-asserted-by":"crossref","first-page":"e01633-17","DOI":"10.1128\/JCM.01633-17","article-title":"Performance of ceftolozane-tazobactam Etest, MIC test strips, and disk diffusion compared to reference broth microdilution for \u03b2-lactam-resistant Pseudomonas aeruginosa isolates","volume":"56","author":"Humphries","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2019111507203119900_dkz379-B55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2019.05.001","article-title":"Comparison of methods to analyse susceptibility of German MDR\/XDR Pseudomonas aeruginosa to ceftazidime\/avibactam","volume":"54","author":"Schaumburg","year":"2019","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/12\/3497\/30795281\/dkz379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/12\/3497\/30795281\/dkz379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T07:21:34Z","timestamp":1573802494000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/12\/3497\/5559553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":55,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,9,3]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz379","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,9,3]]}}}